Scinai Immunotherapeutics Ltd. (FRA:2F5)
Germany · Delayed Price · Currency is EUR 0.8250
+0.0450 (5.77%)
At close: Nov 28, 2025
Scinai Immunotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 0.99 | 1.96 | 4.87 | 14.08 | 17.37 | 2.93 | Upgrade |
Cash & Short-Term Investments | 0.99 | 1.96 | 4.87 | 14.08 | 17.37 | 2.93 | Upgrade |
Cash Growth | -67.85% | -59.67% | -65.40% | -18.99% | 492.87% | -86.03% | Upgrade |
Accounts Receivable | 0.14 | 0.08 | - | - | - | - | Upgrade |
Other Receivables | - | 0.13 | 0.37 | 0.11 | 0.1 | 0.07 | Upgrade |
Receivables | 0.14 | 0.22 | 0.37 | 0.11 | 0.1 | 0.07 | Upgrade |
Prepaid Expenses | 0.24 | 0.08 | 0.07 | 0.05 | 0.23 | 0.3 | Upgrade |
Restricted Cash | 0.14 | 0.13 | 0.14 | 0.14 | 0.14 | - | Upgrade |
Total Current Assets | 1.51 | 2.39 | 5.45 | 14.37 | 17.84 | 3.31 | Upgrade |
Property, Plant & Equipment | 10.33 | 11.06 | 12.03 | 12.7 | 14.19 | 14.25 | Upgrade |
Other Long-Term Assets | - | - | - | - | - | 0.15 | Upgrade |
Total Assets | 11.84 | 13.45 | 17.47 | 27.07 | 32.04 | 17.7 | Upgrade |
Accounts Payable | 0.66 | 0.38 | 0.54 | 0.72 | 1 | 0.58 | Upgrade |
Accrued Expenses | - | 0.78 | 0.85 | 1.24 | 1.07 | 0.39 | Upgrade |
Current Portion of Long-Term Debt | - | - | - | - | - | 18.79 | Upgrade |
Current Portion of Leases | 0.5 | 0.42 | 0.4 | 0.38 | 0.38 | 0.2 | Upgrade |
Current Unearned Revenue | - | 0.23 | - | - | - | - | Upgrade |
Total Current Liabilities | 2.12 | 1.81 | 1.78 | 2.34 | 2.44 | 19.97 | Upgrade |
Long-Term Debt | 0.29 | 0.26 | 19.37 | 20.08 | 27.16 | - | Upgrade |
Long-Term Leases | 1.57 | 1.4 | 0.8 | 1.08 | 1.45 | 1.89 | Upgrade |
Pension & Post-Retirement Benefits | - | - | - | - | - | 0.03 | Upgrade |
Other Long-Term Liabilities | 0 | 0 | 0.1 | 5.33 | - | 0.35 | Upgrade |
Total Liabilities | 3.98 | 3.47 | 22.04 | 28.83 | 31.05 | 22.24 | Upgrade |
Additional Paid-In Capital | 125.64 | 123.63 | 119.51 | 116.08 | 113.08 | 96.49 | Upgrade |
Retained Earnings | -121.67 | -117.54 | -122.34 | -115.84 | -110.04 | -101.03 | Upgrade |
Comprehensive Income & Other | -1.74 | -1.74 | -1.74 | -2.01 | -2.06 | - | Upgrade |
Total Common Equity | 2.23 | 4.35 | -4.57 | -1.76 | 0.98 | -4.54 | Upgrade |
Shareholders' Equity | 7.86 | 9.98 | -4.57 | -1.76 | 0.98 | -4.54 | Upgrade |
Total Liabilities & Equity | 11.84 | 13.45 | 17.47 | 27.07 | 32.04 | 17.7 | Upgrade |
Total Debt | 2.36 | 2.09 | 20.56 | 21.54 | 28.99 | 20.89 | Upgrade |
Net Cash (Debt) | -1.37 | -0.12 | -15.69 | -7.47 | -11.61 | -17.96 | Upgrade |
Net Cash Per Share | -1.04 | -0.15 | -40.17 | -39.61 | -82.26 | -162.08 | Upgrade |
Filing Date Shares Outstanding | 1.51 | 0.85 | 0.46 | 0.33 | 0.19 | 0.12 | Upgrade |
Total Common Shares Outstanding | 1.51 | 0.85 | 0.46 | 0.33 | 0.19 | 0.12 | Upgrade |
Working Capital | -0.61 | 0.59 | 3.67 | 12.03 | 15.4 | -16.66 | Upgrade |
Book Value Per Share | 1.47 | 5.10 | -9.84 | -5.36 | 5.22 | -39.37 | Upgrade |
Tangible Book Value | 2.23 | 4.35 | -4.57 | -1.76 | 0.98 | -4.54 | Upgrade |
Tangible Book Value Per Share | 1.47 | 5.10 | -9.84 | -5.36 | 5.22 | -39.37 | Upgrade |
Machinery | - | 9.92 | 2.46 | 1.92 | 1.23 | 1.14 | Upgrade |
Construction In Progress | - | - | 7.45 | 7.83 | 8.86 | - | Upgrade |
Leasehold Improvements | - | 3.72 | 3.72 | 3.92 | 4.43 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.